ClinicalTrials.gg
CompletedNCT04466891HERIZON-BTC-01Updated Sep 15, 2025Results posted

A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

A Phase 2 interventional study of ZW25 (Zanidatamab) in HER2-amplified Biliary Tract Cancers, sponsored by Jazz Pharmaceuticals. Completed at 67 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 176 studies in Biliary Tract Neoplasms with a site in China — 93 open to participants now, 111 under way, 11 of them phase 3. Biliary Tract Neoplasms · China.

Enrollment
61st of 157
87 · median 62
Started
2020
with 14 others
Phase 2
94 of 176
52 open now
Registered
40th of 176
by date

Among the 176 studies in Biliary Tract Neoplasms with a site in China, this one is the 61st largest by enrollment of the 157 interventional ones that give a count, is one of 15 that started in 2020, is one of 94 in phase 2, and was the 40th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 199 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

93 of the 176 studies in Biliary Tract Neoplasms with a site in China are open now. Recruiting first, the newest first:

88 more — sign in →

All 93 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Biliary Tract Neoplasms with a site in China, or all of them as a file.
02

Study summary

This multicenter, open-label, single-arm trial will evaluate the anti-tumor activity of ZW25 (zanidatamab) monotherapy in subjects with human epidermal growth factor receptor 2 (HER2)-amplified, inoperable and advanced or metastatic biliary tract cancer (BTC), including intra-hepatic cholangiocarcinoma (ICC), extra-hepatic cholangiocarcinoma (ECC), and gallbladder cancer (GBC).

03

Conditions studied

  • HER2-amplified Biliary Tract Cancers

Keywords

  • HER2
  • Bispecific antibody
  • Biparatopic antibody
  • Immunotherapy
  • Biliary Tract Cancer
  • Intra-hepatic cholangiocarcinoma
  • Extra-hepatic cholangiocarcinoma
  • Gallbladder cancer
  • JZP598
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - or cytologically-confirmed BTC, including ICC, ECC or GBC.
  • Locally advanced or BTC and not eligible for curative resection, transplantation, or ablative therapies.
  • Received at least 1 prior gemcitabine-containing systemic chemotherapy regimen for advanced disease, and experienced disease progression after or developed intolerance to the most recent prior therapy. For subjects who received gemcitabine in prior or neoadjuvant treatment, if progression occurred \< 6 months from the latter of primary surgical resection or completion of gemcitabine-containing adjuvant therapy, they will be considered as having received 1 for advanced disease.
  • Subjects must test positive for amplification by ISH-assay at a central laboratory on a new or archival tissue. Note that fine needle aspirates (FNAs; cytology samples) and biopsies from sites of bone metastases are not acceptable. Testing may occur at any time after diagnosis of advanced or metastatic disease and before study enrollment.
  • Male or female, ≥18 years of age (or the legal age of adulthood per country-specific regulations).
  • (ECOG) performance status ≤ 1.
  • Adequate organ function.
  • Adequate cardiac function, as defined by ≥ 50%.

Exclusion criteria

Exclusion Criteria:

  • Received systemic anti-cancer therapy within 3 weeks of the first dose of ZW25. Received radiotherapy within 2 weeks of the first dose of ZW25.
  • Prior treatment with -targeted agents.
  • Untreated central nervous system (CNS) , symptomatic , or radiation treatment for CNS metastases within 4 weeks of start of study treatment. Stable, treated brain metastases are allowed (defined as subjects who are off and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks at the time of screening).
  • Known (LMD). If LMD has been reported radiographically on baseline MRI, but is not suspected clinically by the investigator, the subject must be free of neurological symptoms of LMD.
  • Concurrent uncontrolled or active hepatobiliary disorders or untreated or ongoing complications after laparoscopic procedures or stent placement, including but not limited to active cholangitis, unresolved biliary obstruction, infected biloma or abscess. Any complications must be resolved more than 2 weeks prior to the first dose of ZW25.
  • Prior or concurrent whose natural history or treatment has, in the opinion of the investigator or medical monitor, the potential to interfere with the safety or efficacy assessment of the regimen.
  • Active hepatitis
  • Infection with (HIV)-1 or HIV-2
  • Fridericia (QTcF) > 470 ms.
  • History of myocardial infarction or unstable angina within 6 months prior to enrollment, troponin levels consistent with myocardial infarction, or cardiac disease.
  • Acute or chronic uncontrolled pancreatitis or Class C liver disease.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    ZW25 (Zanidatamab) Monotherapy

    Drug: ZW25 (Zanidatamab)

Interventions

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR)

    Number of participants who achieved a confirmed best overall response (BOR) of either complete response (CR) or partial response (PR) during treatment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete response (CR) is defined as a disappearance of all target and non-target lesions and partial response (PR) is defined as at least a 30% decrease in the sum of diameters of all target lesions.

    Time frame: Up to 34 months

Secondary outcomes

  1. Duration of Response (DOR) by ICR

    The time from the first confirmed objective response (CR or PR) to documented progressive disease (PD) per RECIST 1.1, or death from any cause

    Time frame: Up to 45 months

  2. DOR ≥ 16 Weeks by ICR

    Proportion of subjects with a DOR ≥ 16 weeks per RECIST 1.1

    Time frame: 24 weeks, up to 45 months

  3. Disease Control Rate (DCR) by ICR

    Number of subjects who achieved a best overall response of stable disease (SD), non-CR/non-PD, or confirmed CR or PR per RECIST 1.1

    Time frame: Up to 45 months

  4. Progression-free Survival (PFS) by ICR

    The time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), or death from any cause

    Time frame: Up to 45 months

  5. ORR by Investigator Assessment

    Number of subjects who achieved a confirmed BOR of either CR or PR during treatment per RECIST 1.1

    Time frame: Up to 45 months

  6. DOR by Investigator Assessment

    The time from the first confirmed objective response (CR or PR) to documented progressive disease (PD) per RECIST 1.1, or death from any cause

    Time frame: Up to 45 months

  7. DOR ≥ 16 Weeks by Investigator Assessment

    Proportion of subjects with a DOR ≥ 16 weeks per RECIST 1.1

    Time frame: 24 weeks, up to 45 months

  8. DCR by Investigator Assessment

    Number of subjects who achieved a best overall response of stable disease (SD), non-CR/non-PD, or confirmed CR or PR per RECIST 1.1

    Time frame: Up to 45 months

  9. PFS by Investigator Assessment

    The time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), or death from any cause

    Time frame: Up to 45 months

  10. Overall Survival

    The time from the first dose of study treatment until the date of death from any cause

    Time frame: Up to 45 months

  11. Incidence of Adverse Events (AEs)

    Number of subjects who experienced AEs or serious adverse events

    Time frame: Up to 45 months

  12. Incidence of Laboratory Abnormalities

    Number of subjects who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

    Time frame: Up to 45 months

  13. Maximum Serum Concentration of ZW25

    Time frame: Pre-dose, end of infusion, 2, 4, 8, 24 and 96 hours post dose

  14. Trough Concentration of ZW25

    Minimum observed serum concentration (trough)

    Time frame: Pre-dose, end of infusion, 2, 4, 8, 24 and 96 hours post dose

  15. Incidence of Anti-drug Antibodies (ADAs)

    Number of subjects who develop ADAs

    Time frame: Up to 45 months

07

Results

Posted Aug 21, 2024

Participant flow

A total of 87 participants who met all eligibility criteria were enrolled and received treatment.

Participant flow — Overall Study
MilestoneCohort ICohort II
Started807
Completed00
Not completed807
Withdrew: Death606
Withdrew: Withdrawal by subject81
Withdrew: Study terminated by sponsor50
Withdrew: Lost to follow-up20
Withdrew: Transitioned to named patient supply (nps) program50

Outcome measures

PrimaryConfirmed Objective Response Rate (ORR) by Independent Central Review (ICR)

Number of participants who achieved a confirmed best overall response (BOR) of either complete response (CR) or partial response (PR) during treatment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Complete response (CR) is defined as a disappearance of all target and non-target lesions and partial response (PR) is defined as at least a 30% decrease in the sum of diameters of all target lesions.

Time frame:
Up to 34 months
Reported as:
Count of participants · Participants
Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR)
ParticipantsCohort ICohort II
Confirmed Objective Response Rate (ORR) by Independent Central Review (ICR)330
SecondaryDuration of Response (DOR) by ICR

The time from the first confirmed objective response (CR or PR) to documented progressive disease (PD) per RECIST 1.1, or death from any cause

Time frame:
Up to 45 months
Reported as:
Median · months
Duration of Response (DOR) by ICR
monthsCohort ICohort II
Duration of Response (DOR) by ICR14.92 (7.39 to 23.98)—
SecondaryDOR ≥ 16 Weeks by ICR

Proportion of subjects with a DOR ≥ 16 weeks per RECIST 1.1

Time frame:
24 weeks, up to 45 months
Reported as:
Count of participants · Participants
DOR ≥ 16 Weeks by ICR
ParticipantsCohort ICohort II
DOR ≥ 16 Weeks by ICR28—
SecondaryDisease Control Rate (DCR) by ICR

Number of subjects who achieved a best overall response of stable disease (SD), non-CR/non-PD, or confirmed CR or PR per RECIST 1.1

Time frame:
Up to 45 months
Reported as:
Count of participants · Participants
Disease Control Rate (DCR) by ICR
ParticipantsCohort ICohort II
Disease Control Rate (DCR) by ICR553
SecondaryProgression-free Survival (PFS) by ICR

The time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), or death from any cause

Time frame:
Up to 45 months
Reported as:
Median · months
Progression-free Survival (PFS) by ICR
monthsCohort ICohort II
Progression-free Survival (PFS) by ICR5.49 (3.65 to 7.29)1.87 (1.22 to NA)
SecondaryORR by Investigator Assessment

Number of subjects who achieved a confirmed BOR of either CR or PR during treatment per RECIST 1.1

Time frame:
Up to 45 months
Reported as:
Count of participants · Participants
ORR by Investigator Assessment
ParticipantsCohort ICohort II
ORR by Investigator Assessment340
SecondaryDOR by Investigator Assessment

The time from the first confirmed objective response (CR or PR) to documented progressive disease (PD) per RECIST 1.1, or death from any cause

Time frame:
Up to 45 months
Reported as:
Median · months
DOR by Investigator Assessment
monthsCohort ICohort II
DOR by Investigator Assessment11.10 (7.46 to 14.06)—
SecondaryDOR ≥ 16 Weeks by Investigator Assessment

Proportion of subjects with a DOR ≥ 16 weeks per RECIST 1.1

Time frame:
24 weeks, up to 45 months
Reported as:
Count of participants · Participants
DOR ≥ 16 Weeks by Investigator Assessment
ParticipantsCohort ICohort II
DOR ≥ 16 Weeks by Investigator Assessment31—
SecondaryDCR by Investigator Assessment

Number of subjects who achieved a best overall response of stable disease (SD), non-CR/non-PD, or confirmed CR or PR per RECIST 1.1

Time frame:
Up to 45 months
Reported as:
Count of participants · Participants
DCR by Investigator Assessment
ParticipantsCohort ICohort II
DCR by Investigator Assessment541
SecondaryPFS by Investigator Assessment

The time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), or death from any cause

Time frame:
Up to 45 months
Reported as:
Median · months
PFS by Investigator Assessment
monthsCohort ICohort II
PFS by Investigator Assessment5.37 (3.55 to 7.29)1.77 (0.79 to 1.94)
SecondaryOverall Survival

The time from the first dose of study treatment until the date of death from any cause

Time frame:
Up to 45 months
Reported as:
Median · months
Overall Survival
monthsCohort ICohort II
Overall Survival15.54 (10.38 to 18.66)5.52 (1.22 to NA)
SecondaryIncidence of Adverse Events (AEs)

Number of subjects who experienced AEs or serious adverse events

Time frame:
Up to 45 months
Reported as:
Count of participants · Participants
Incidence of Adverse Events (AEs)
ParticipantsCohort ICohort II
Any Treatment Emergent Adverse Event (TEAE)786
Zanidatamab related TEAE612
Any Treatment Emergent Serious Adverse Event433
Zanidatamab related serious TEAE80
Zanidatamab related TEAE resulting in treatment discontinuation20
SecondaryIncidence of Laboratory Abnormalities

Number of subjects who experienced a maximum severity of Grade 3 or higher post-baseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 5.0

Time frame:
Up to 45 months
Reported as:
Count of participants · Participants
Incidence of Laboratory Abnormalities
ParticipantsCohort ICohort II
Incidence of Laboratory Abnormalities377
SecondaryMaximum Serum Concentration of ZW25
Time frame:
Pre-dose, end of infusion, 2, 4, 8, 24 and 96 hours post dose
Reported as:
Geometric mean · micrograms per milliliter
Maximum Serum Concentration of ZW25
micrograms per milliliterCohort ICohort II
Maximum Serum Concentration of ZW25457.6 ± 15.44443.6 ± 24.10
SecondaryTrough Concentration of ZW25

Minimum observed serum concentration (trough)

Time frame:
Pre-dose, end of infusion, 2, 4, 8, 24 and 96 hours post dose
Reported as:
Geometric mean · micrograms per milliliter
Trough Concentration of ZW25
micrograms per milliliterCohort ICohort II
Trough Concentration of ZW2573.4 ± 42.1046.5 ± 18.66
SecondaryIncidence of Anti-drug Antibodies (ADAs)

Number of subjects who develop ADAs

Time frame:
Up to 45 months
Reported as:
Count of participants · Participants
Incidence of Anti-drug Antibodies (ADAs)
ParticipantsCohort ICohort II
Incidence of Anti-drug Antibodies (ADAs)10

Adverse events

Collected over Adverse events were collected from the start of dosing of any study drug up until 30 days after last study dose, up to approximately 45 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort I60/80 (75%)43/80 (53.8%)78/80 (97.5%)
Cohort II6/7 (85.7%)3/7 (42.9%)5/7 (71.4%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventCohort ICohort II
CholangitisHepatobiliary disorders3/802/7
Hepatitis cholestaticHepatobiliary disorders0/801/7
PneumoniaInfections and infestations4/801/7
Biliary sepsisInfections and infestations0/801/7
Pneumocystis jirovecii pneumoniaInfections and infestations0/801/7
DyspepsiaGastrointestinal disorders0/801/7
HaematemesisGastrointestinal disorders1/801/7
Multiple organ dysfunction syndromeGeneral disorders0/801/7
Pleural effusionRespiratory, thoracic and mediastinal disorders1/801/7
Jaundice cholestaticHepatobiliary disorders5/800/7
Most frequent other events
Showing 10 of 50
Most frequent other events
EventCohort ICohort II
DiarrhoeaGastrointestinal disorders39/800/7
AnemiaBlood and lymphatic system disorders18/803/7
Infusion related reactionInjury, poisoning and procedural complications27/801/7
Blood alkaline phosphatase increasedInvestigations7/802/7
Abdominal painGastrointestinal disorders16/800/7
Alanine aminotransferase increasedInvestigations16/801/7
Aspartate aminotransferase increasedInvestigations15/801/7
NauseaGastrointestinal disorders14/800/7
PyrexiaGeneral disorders14/800/7
VomitingGastrointestinal disorders13/801/7

Baseline characteristics

The baseline demographic characteristics were assessed in the Safety Analysis Set.

Age, Continuous
Age, Continuous(years)Cohort ICohort IITotal
Mean62.5 ± 9.5665.4 ± 8.7562.7 ± 9.48
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ICohort IITotal
Female45247
Male35540
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort ICohort IITotal
Hispanic or Latino516
Not Hispanic or Latino72678
Unknown or Not Reported303
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort ICohort IITotal
American Indian or Alaska Native101
Asian52557
Native Hawaiian or Other Pacific Islander000
Black or African American000
White23225
More than one race000
Unknown or Not Reported404
08

Study locations

67 sites
  • Banner MD Anderson Cancer Center
    Gilbert, Arizona 85234, United States
  • University of Arizona Cancer Center
    Tucson, Arizona 95724, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of California Los Angeles
    Santa Monica, California 90404, United States
  • The Oncology Institute of Hope and Innovation
    Whittier, California 90603, United States
  • Advent Health Cancer Institute
    Orlando, Florida 32804, United States
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
  • University of Maryland Greenebaum Cancer Center
    Baltimore, Maryland 21201, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Texas Southwestern Medical Center - Hospital
    Dallas, Texas 75390, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • Centro de Cáncer Nuestra Señora de la Esperanza
    Santiago, 8330032, Chile
  • Radiomed (Clinica Alemana de Temuco)
    Temuco, 645, Chile
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Peking Union Medical College Hospital
    Beijing, 100730, China
  • Jilin Cancer Hospital
    Changchun, 130012, China
  • Hunan Cancer Hospital
    Changsha, 410013, China
  • West China Hospital
    Chengdu, 610041, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, 510080, China
  • The First Affiliated Hospital of Zhejiang University
    Hangzhou, 310003, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, 310014, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, 310016, China
  • Zhejiang Cancer Hospital
    Hangzhou, 310022, China
  • Affiliated Tumor Hospital of Harbin Medical University
    Harbin, 150081, China
  • Anhui Provincial Hospital
    Hefei, 230001, China
  • Huzhou Central Hospital
    Huzhou, 313000, China
  • Jinhua Central Hospital
    Jinhua, 321000, China
  • The First Hospital Of Lanzhou University
    Lanzhou, 730000, China
  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
    Nanjing, 210008, China
  • Shandong Provincial Third Hospital
    Shandong, 250031, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, 200032, China
  • The Third Affiliated Hospital of the Chinese PLA
    Shanghai, 200081, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, 300060, China
  • Weifang People's Hospital
    Weifang, 261000, China
  • Hubei Cancer Hospital
    Wuhan, 430079, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, 450052, China
  • Oncologie médicale Hopital Jean Minjoz
    Besançon, 25030, France
  • Institut de Cancerologie et d'Hematologie Hopital Morvan - CHRU de Brest
    Brest, 29200, France
  • Hopitaux de La Timone
    Marseille, 13385, France
  • Département Oncologie Gastro-entérologie CHRU de Poitiers La Miletrie
    Poitiers, 86000, France
  • Département De Médecine
    Villejuif, 94805, France
  • Fondazione del Piemonte per l'Oncologia (IRCCS)
    Candiolo, 10060, Italy
  • Istituto Clinico Humanitas
    Milan, 20089, Italy
  • Istituto Nazionale Dei Tumori
    Milan, 20133, Italy
  • Istituto Oncologico Veneto - I.R.C.C.S.
    Padova, 35128, Italy
  • Gyeongsang National University Hospital
    Jinju, 52727, South Korea
  • Pusan National University Hospital
    Pusan, 49241, South Korea
  • Seoul National University Bundang Hospital
    Seongnam, 13620, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital Yonsei University Health System
    Seoul, 03722, South Korea
  • Asan Medical Center Hospital
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 06591, South Korea
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Universitario Germans Trias i Pujol
    Barcelona, 08916, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28007, Spain
  • Hospital Universitario Doce de Octubre
    Madrid, 28041, Spain
  • Corporacio Sanitaria Parc Tauli
    Sabadell, 08208, Spain
  • Hospital Miguel Servet
    Zaragoza, 50009, Spain
  • University College London Hospitals (UCLH)
    London, NW1 2PG, United Kingdom
  • Royal Free London NHS Foundation Trust
    London, NW3 2QG, United Kingdom
  • Imperial College Healthcare NHS Trust
    London, W12 0HS, United Kingdom
09

References and documents

Publications

  • Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Lindsey S, Bachini M, Morement H, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group. A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer. Future Oncol. 2024;20(31):2319-2329. doi: 10.1080/14796694.2024.2368952. Epub 2024 Aug 8. PubMed 39114870 ↗
  • Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023 Jul;24(7):772-782. doi: 10.1016/S1470-2045(23)00242-5. Epub 2023 Jun 2. PubMed 37276871 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.

Data sharing details ↗ · www.jazzpharma.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jul 2023, 33 months.

Results were first posted in Aug 2024, 1 year after primary completion.

Of 129 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 68. This study's 33 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2020
First posted
Jul 10, 2020
StartActual
Oct 1, 2020
Primary completionActual
Jul 28, 2023
CompletionActual
Jul 11, 2024
Results first posted
Aug 21, 2024
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04466891
Collaborators
BeiGene, Jazz Pharmaceuticals Ireland Limited, BeOne Medicines LTD
Responsible party
Sponsor
First posted
Jul 10, 2020
Start date
Oct 1, 2020
Primary completion
Jul 28, 2023
Completion
Jul 11, 2024
Results posted
Aug 21, 2024
Last update
Sep 15, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanidatamab

Start the discussion